Resultado de búsqueda
View Jerry McMahon’s profile on LinkedIn, a professional community of 1 billion members. Dr. McMahon brings more than 30 years of exceptional biotechnology leadership, scientific…
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
26 de oct. de 2021 · Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer. Scott Myers, Current Member of Harpoon’s Board of Directors Named Chair, Replacing Ron Hunt...
26 de oct. de 2021 · Eastland will succeed Jerry McMahon, Ph.D., who has resigned from his position as President and Chief Executive Officer and as a member of the company’s Board of Directors (the “Board”). Dr....
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
7 de sept. de 2022 · STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
7 de sept. de 2022 · 7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board ...
